Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Banque Cantonale Vaudoise

Banque Cantonale Vaudoise raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,835 shares of the medical equipment provider’s stock after acquiring an additional 3,682 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Hologic were worth $3,163,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in HOLX. Innealta Capital LLC bought a new stake in Hologic during the second quarter worth approximately $25,000. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the 3rd quarter worth $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the 1st quarter worth $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic during the second quarter worth $37,000. Finally, Cromwell Holdings LLC lifted its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $78.57 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.25 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a 50 day moving average price of $80.56 and a two-hundred day moving average price of $78.30.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the business earned $0.89 EPS. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HOLX shares. Mizuho cut their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Stephens reaffirmed an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Raymond James raised their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.